- Home
- AEMD vs ENVB Comparison
AEMD vs ENVB Comparison
Compare AEMD & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEMD | ENVB |
|---|---|---|
| Founded | 1984 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 3.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AEMD | ENVB |
|---|---|---|
| Price | $3.17 | $4.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $287.50 | $120.00 |
| AVG Volume (30 Days) | ★ 70.4K | 53.6K |
| Earning Date | 02-11-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.22 | $3.50 |
| 52 Week High | $64.00 | $61.18 |
Technical Indicators
Market Signals| Indicator | AEMD | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 55.77 | 48.10 |
| Support Level | $2.64 | $3.76 |
| Resistance Level | $3.19 | $4.24 |
| Average True Range (ATR) | 0.30 | 0.28 |
| MACD | 0.10 | 0.08 |
| Stochastic Oscillator | 87.96 | 88.72 |
Price Performance
Historical ComparisonAbout AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.